Evidence map›Paper›PMID 21491104›Full record

ArticleInternational journal of hematology2011

Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Ayako Arai, Ken-Ichi Imadome, Yuko Watanabe, Mayumi Yoshimori, Takatoshi Koyama, Takeharu Kawaguchi, Chiaki Nakaseko, Shigeyoshi Fujiwara, Osamu Miura

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. A rare B-cell type chronic active Epstein-Barr virus infection patient mimicking lymphoma onAmerican journal of nuclear medicine and molecular imaging · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayako AraiDepartment of Hematology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo, 113-8519, Japan. ara.hema@tmd.ac.jp.
Ken-Ichi ImadomeDepartment of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan.
Yuko WatanabeDepartment of Hematology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo, 113-8519, Japan.
Mayumi YoshimoriDepartment of Laboratory Molecular Genetics of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
Takatoshi KoyamaDepartment of Laboratory Molecular Genetics of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
Takeharu KawaguchiDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Shigeyoshi FujiwaraDepartment of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan.
Osamu MiuraDepartment of Hematology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo, 113-8519, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed a retrospective analysis of patients with adult-onset chronic active Epstein-Barr virus infection (CAEBV). First, we analyzed five patients (aged 28-72) diagnosed at our hospitals with EBV-infected clonally proliferating T cells. Four patients were administered cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) chemotherapy, but no remarkable decrease of viral load was observed in three of the patients. The other patient died 19 days after initiation of CHOP treatment due to disease progression. Addition of high-dose cytarabine to the regimens of two of the patients was discontinued shortly after administration, due to the development of grade 4 pericardial effusion. Together, these regimens may be insufficient for treating adult-onset CAEBV. We next reviewed 23 adult-onset CAEBV patients, adding 18 previously reported patients to the five patients described in the present study. T cells were frequently infected (87%), whereas NK- and T-cell types are known to be almost equally prevalent in childhood-onset cases. The time duration from the onset of disease to initiation of treatment averaged 20 months. Reports showed that 12 patients died; seven patients died at an average of 8 months after initiation of treatment. Patients' disease courses seemed to be rapidly progressive and more aggressive than those of childhood-onset cases. More cases must be studied to clarify clinical features and establish an optimal treatment strategy.

Indexed as

AdultAgedAge of OnsetAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseCyclophosphamideCytarabineDoxorubicinDrug Administration ScheduleEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansJapanMaleAntineoplastic AgentsAsparaginaseCyclophosphamideCytarabineDoxorubicinPrednisoneVincristine

Identifiers

PMID21491104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.